GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Net Cash per Share

Synthorx (Synthorx) Net Cash per Share : $4.37 (As of Sep. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Synthorx Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Synthorx's Net Cash per Share for the quarter that ended in Sep. 2019 was $4.37.

The historical rank and industry rank for Synthorx's Net Cash per Share or its related term are showing as below:

THOR's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.87
* Ranked among companies with meaningful Price-to-Net-Cash only.

Synthorx Net Cash per Share Historical Data

The historical data trend for Synthorx's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Net Cash per Share Chart

Synthorx Annual Data
Trend Dec16 Dec17 Dec18
Net Cash per Share
-0.83 -1.54 5.77

Synthorx Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Net Cash per Share Get a 7-Day Free Trial Premium Member Only 1.92 5.77 5.35 4.89 4.37

Competitive Comparison of Synthorx's Net Cash per Share

For the Biotechnology subindustry, Synthorx's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthorx's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Synthorx's Price-to-Net-Cash falls into.



Synthorx Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Synthorx's Net Cash per Share for the fiscal year that ended in Dec. 2018 is calculated as

Net Cash per Share (A: Dec. 2018 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(188.356-7.146-0)/31.3948
=5.77

Synthorx's Net Cash per Share for the quarter that ended in Sep. 2019 is calculated as

Net Cash per Share (Q: Sep. 2019 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(150.886-11.708-0)/31.8651
=4.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synthorx  (NAS:THOR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Synthorx Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Synthorx's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthorx (Synthorx) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037
Executives
Powell Andrew Kenneth William director C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver director, officer: President and CEO 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022